Heat Biologics, Inc.
(NASDAQ : HTBX)

( )
HTBX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -4.21%212.040.0%$1971.46m
BIIBBiogen, Inc. -0.67%371.901.7%$1288.80m
NVAXNovavax, Inc. -1.10%192.2479.8%$820.37m
SNSSSunesis Pharmaceuticals, Inc. -5.76%11.130.7%$778.03m
AMGNAmgen, Inc. -0.50%238.711.3%$637.40m
BNTXBioNTech SE -2.96%229.500.0%$572.94m
VRTXVertex Pharmaceuticals, Inc. -0.72%187.521.9%$527.63m
GILDGilead Sciences, Inc. -0.60%66.651.0%$475.82m
REGNRegeneron Pharmaceuticals, Inc. -0.79%529.802.7%$386.12m
ILMNIllumina, Inc. 0.74%469.133.5%$346.93m
OCGNOcugen, Inc. 2.02%7.560.0%$345.77m
ALXNAlexion Pharmaceuticals, Inc. 0.11%179.832.0%$331.72m
TXG10X Genomics, Inc. 2.16%201.410.0%$178.72m
EXASEXACT Sciences Corp. 2.37%130.9718.1%$176.05m
BNGOBionano Genomics, Inc. 1.68%7.250.0%$156.12m

Company Profile

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.